Imagion Biosystems Resumes Nanoparticle Manufacturing
Key points
- Master Service Agreement with CDMO in place
- Manufacturing capabilities aligned with FDA quality requirements
- Supports strategic business plan and potential commercialization
Full summary
Imagion Biosystems Limited (ASX: IBX) has resumed manufacturing capabilities for its MagSense® nanoparticles through a Master Service Agreement with nanoComposix, a CDMO. This partnership aims to align manufacturing with U.S. FDA quality requirements, supporting the company's strategic business plan and potential commercialization of MagSense® technology. The agreement allows Imagion to leverage nanoComposix's capabilities to produce pharmaceutical-grade material, reducing operational costs and ensuring product specifications are met for regulatory submissions.
Summary generated by a large language model. Please interpret with care.